Management of Hypomagnesemia in Patients Taking Tacrolimus

Monitoring and Supplementation

Regular monitoring and aggressive supplementation of magnesium is essential for patients on tacrolimus therapy to prevent hypomagnesemia-related complications including renal impairment and encephalopathy 1, 2
Serum magnesium levels should be monitored regularly in all patients on tacrolimus therapy (Grade 1B recommendation) 1, 3
Initial monitoring should occur at least every 4-6 weeks to detect tacrolimus-induced abnormalities 2
Monitoring should be intensified when patients are hospitalized with complications 2
Measure serum magnesium levels regularly as part of routine blood work 1, 2
Assess for symptoms of hypomagnesemia (muscle cramps, tremors, seizures, arrhythmias) 4
Loop diuretics should be avoided or minimized 4
If hypomagnesemia persists despite supplementation, consider reducing tacrolimus target dose concentration if clinically appropriate 3

Failing to monitor magnesium levels regularly in patients on tacrolimus can lead to serious complications 1, 2
Not accounting for drug interactions that affect tacrolimus levels and consequently magnesium excretion can worsen hypomagnesemia 2